Does thiamine supplementation affect heart failure? A systematic review and meta-analysis of randomized control trials

Syed, Abdul Rehman Shah; Ahad, Syed Abdul; Akram, Abdullah; Azam, Muhammad Shaheryar; Muzammil, Muhammad Ali; Ansari, Ayesha Irshad; Eqbal, Farea; Farooq, Muhammad Haris; Khatri, Mahima; Kumar, Satesh; Kumar, Nomesh

doi:10.1016/j.hrtlng.2023.04.011

Cited by 17 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another comprehensive review and meta-analysis compared thiamine supplementation to placebo for HF patients. This study found that thiamine supplementation did not affect HF outcomes except for heart rate [22].…”

Section: The Impact Of Thiamine On Cardiac Disordersmentioning

confidence: 50%

Metabolic failure due to thiamine deficiency during critical illness

Cobilinschi,

Andrei,

Grinţescu

et al. 2024

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

Purpose of review Thiamine is a crucial component in cellular energy metabolism, serving as a cofactor for multiple enzymatic processes and also having a role in regulating neuronal and neuromuscular transmission. Also it exerts antioxidant proprieties. The objective of this review is to consolidate and assess the most recent research concerning the consequences of insufficient thiamine levels for critically ill patients and to examine thiamine-related interventions. Recent findings Recent studies have unveiled a noteworthy association between thiamine deficiency and unfavorable consequences, such as heightened morbidity and fatality rates. The aforementioned deficiency exhibits a significant presence in medical situations such as starvation and alcohol use disorder, but also in patients during critical illness. Thiamine deficiency can have significant metabolic implications resulting in compromised energy generation and organ dysfunction, warranting prompt recognition and management. Summary Thiamine deficiency may not be recognized in critical care. Timely identification and management are imperative to mitigate adverse outcomes and improve patient prognosis. Thiamine may offer benefits for specific patient groups at higher risk of deficiency. Future studies should focus to establish optimal dosing, timing, and monitoring strategies on understanding the pathophysiological changes associated with thiamine deficiency in ICU patients and clarify its role in improving clinical outcomes.

show abstract

Section: The Impact Of Thiamine On Cardiac Disordersmentioning

confidence: 50%

Metabolic failure due to thiamine deficiency during critical illness

Cobilinschi,

Andrei,

Grinţescu

et al. 2024

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

show abstract

“…A recent meta‐analysis of six RCTs found that thiamine supplementation did not significantly impact the outcomes of patients with HF [ 11 ]. However, we have noted that one of the studies included in this analysis employed a combination of high‐dose micronutrients (vitamin A, thiamine, vitamin C, vitamin D, etc.)…”

Section: Discussionmentioning

confidence: 99%

“…However, with the increasing number of clinical trials conducted on this aspect, the role of thiamine in CHF has been subject to challenge. Recently, a meta‐analysis revealed that thiamine failed to improve outcomes in patients with HF [ 11 ]. However, it is noteworthy that this study encompassed both acute heart failure (AHF) and CHF, which are characterized by distinct pathophysiological mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Role of Thiamine Supplementation in the Treatment of Chronic Heart Failure: An Updated Meta‐Analysis of Randomized Controlled Trials

He,

Wang,

et al. 2024

Clinical Cardiology

View full text Add to dashboard Cite

BackgroundChronic heart failure (CHF) has always posed a significant threat to human survival and health. The efficacy of thiamine supplementation in CHF patients remains uncertain.HypothesisReceiving supplementary thiamine may not confer benefits to patients with CHF.MethodsA comprehensive search was conducted across the Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases up until May 2023 to identify articles investigating the effects of thiamine supplementation in CHF patients. Predefined criteria were utilized for selecting data on study characteristics and results.ResultsSeven randomized, double‐blind, controlled trials (five parallel trials and two crossover trials) involving a total of 274 patients were enrolled. The results of the meta‐analysis pooling these studies did not reveal any significant effect of thiamine treatment compared with placebo on left ventricular ejection fraction (WMD = 1.653%, 95% CI: −1.098 to 4.405, p = 0.239, I2 = 61.8%), left ventricular end‐diastolic volume (WMD = −6.831 mL, 95% CI: −26.367 to 12.704, p = 0.493, I2 = 0.0%), 6‐min walking test (WMD = 16.526 m, 95% CI: −36.582 to 69.634, p = 0.542, I2 = 66.3%), N‐terminal pro‐B type natriuretic peptide (WMD = 258.150 pg/mL, 95% CI: −236.406 to 752.707, p = 0.306, I2 = 21.6%), or New York Heart Association class (WMD = −0.223, 95% CI: −0.781 to 0.335, p = 0.434, I2 = 87.1%). However, it effectively improved the status of thiamine deficiency (TD).ConclusionsOur meta‐analysis indicates that thiamine supplementation does not have a direct therapeutic effect on CHF, except for correcting TD.

show abstract

“…To assess which of the PT arm or TC arm was better, we extracted the means and standard deviations for the following continuous outcomes: PFS, QoL, and OS. If any study reported the values in IQR, we calculated the SD using the following equation: SD= Change in IQR/1.35 [ 15 ].…”

Section: Reviewmentioning

confidence: 99%

Comparison of the Efficacy of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Improving Survival and Quality of Life in the Advanced Ovarian Cancer Patient Population: A Systematic Review and Meta-Analysis of Randomized Control Trials

Mansoor,

Shakil,

Jalal

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

Ovarian cancer, being one of the prevalent gynecological cancers, warrants a therapy that’s both effective and well tolerated. After extensive drug testing, combination regimens with paclitaxel plus platinum-based agents such as cisplatin/carboplatin and taxanes, have shown promising results for advanced ovarian cancer. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to compare the efficacy of two treatment regimens for advanced ovarian cancer: cisplatin/paclitaxel and carboplatin/paclitaxel. PubMed (Medline), Science Direct, and Cochrane Library were searched from inception to March 2023. The meta-analysis included patients with histologically verified International Federation of Gynaecology and Obstetrics (FIGO) stages IIB to IV ovarian carcinoma who received either carboplatin/paclitaxel or cisplatin/paclitaxel. The primary outcomes were progression-free survival (PFS), overall survival (OS), quality of life (QOL), complete response rate (CRR), and partial response rate (PRR). The revised Cochrane Risk of Bias Tool 2.0 was used to assess the quality of the RCTs The five RCTs chosen for this statistical analysis consisted of a total of 2239 participants, with 1109 receiving paclitaxel/cisplatin for treatment and the remaining 1130 receiving carboplatin/paclitaxel. Among all included outcomes, these reported significant findings: QoL (p-value=0.0002), thrombocytopenia (p=<0.00001), neurological toxicity (p-value=0.003), nausea/vomiting (p-value=<0.00001), myalgia/arthralgia (p-value=0.02), and febrile neutropenia (p-value=0.01). We concluded that the carboplatin/paclitaxel doublet endows a better quality of life (QOL) to patients along with significantly fewer gastrointestinal and neurological toxicities when compared with the cisplatin/paclitaxel combination. However, the myelosuppressive effects of carboplatin/paclitaxel remain a point of concern and may require clinical management.

show abstract

Does thiamine supplementation affect heart failure? A systematic review and meta-analysis of randomized control trials

Cited by 17 publications

References 34 publications

Metabolic failure due to thiamine deficiency during critical illness

Metabolic failure due to thiamine deficiency during critical illness

Role of Thiamine Supplementation in the Treatment of Chronic Heart Failure: An Updated Meta‐Analysis of Randomized Controlled Trials

Comparison of the Efficacy of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Improving Survival and Quality of Life in the Advanced Ovarian Cancer Patient Population: A Systematic Review and Meta-Analysis of Randomized Control Trials

Contact Info

Product

Resources

About